Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
alright :):):):) im with yall!
love this company just be patient!
you got me lol.
DEAR 1.74$ moving nicely.
PRESS RELEASE: Lazard World Dividend & Income Fund Declares Monthly Distribution
PRESS RELEASE: Lazard World Dividend & Income Fund Declares Monthly Distribution
NEW YORK--(BUSINESS WIRE)--November 15, 2010--
The Board of Directors of Lazard World Dividend & Income Fund, Inc. (the "Fund") (NYSE:LOR) has authorized the Fund to declare today, pursuant to a level distribution policy, a monthly distribution of $0.07063 per share on the Fund´s outstanding common stock. The distribution is payable on December 23, 2010 to shareholders of record on December 13, 2010. The ex-dividend date is December 9, 2010.
Portfolio data as of October 31, 2010, including performance, asset allocation, top 10 holdings, sector weightings, regional exposure, and other Fund characteristics have been posted on Lazard Asset Management LLC´s ("LAM") website, www.LazardNet.com. Additionally, the notice required by Section 19(a) of the Investment Company Act of 1940, as amended, which provides information regarding the respective estimated amounts of each monthly distribution derived from net investment income, net realized capital gains (short- and long-term) and return of capital, will also be available on www.LazardNet.com.
The Fund´s objective is total return, through a combination of dividends income, and capital appreciation. The Fund´s net assets are invested in a portfolio of approximately 60 to 90 world equity securities, consisting primarily of the highest dividend-yielding stocks selected from the current holdings of other accounts managed by LAM. The equity portfolio is broadly diversified in both developed and emerging market countries and across the capitalization spectrum. The Fund seeks enhanced income by investing in short duration (typically below one year) emerging market forward currency contracts and other emerging market debt instruments.
An indirect subsidiary of Lazard Ltd (NYSE: LAZ), LAM, the Fund´s investment manager, offers a range of equity, fixed-income, and alternative investment products worldwide. As of September 30, 2010, LAM and affiliated asset management companies in the Lazard Group managed approximately $144 billion worth of client assets. For more information about LAM, please go to www.LazardNet.com.
CONTACT: Lazard Ltd
Media:
Judi Mackey,
212-632-1428
judi.mackey@lazard.com
or
Investor:
Ben Wulfsohn,
800-823-6300
ben.wulfsohn@lazard.com
SOURCE: Lazard World Dividend & Income Fund, Inc.
Copyright Business Wire 2010
Click here to go to Dow Jones NewsPlus, a web front page of today´s most important business and market news, analysis and commentary: http://www.djnewsplus.com/access/al?rnd=2zlvsloiAKV80fycieqqWg%3D%3D. You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
November 15, 2010 09:36 ET (14:36 GMT)
DEAR is holding up well in this crazy market. looking for a buying opurturnity.
LCC 10.85$ did we see the low for the moment?
DEAR 1.74$ watch for potential move further.
slightly under the 200 day MA 1.79 and aboove the 50 day MA 1.62$.
the price sticks in between thoose two lines. it will breakout from here its just a matter of time and direction the break will go.
ENS HOD 29.42$
EnerSys announced that for third quarter of 2011, it expects adjusted net earnings per diluted share (EPS) to be between $0.59 and $0.63, which excludes an expected charge of $0.06 from our ongoing restructuring programs and acquisition expenses. According to Reuters Estimates, analysts on an average are expecting the Company to report EPS of $0.56 for third quarter of 2011.
http://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=ENS×tamp=20101109215300
ENS HOD 29.42$
EnerSys Issues Q3 2011 EPS Guidance
Tuesday, 9 Nov 2010 04:53pm EST
EnerSys announced that for third quarter of 2011, it expects adjusted net earnings per diluted share (EPS) to be between $0.59 and $0.63, which excludes an expected charge of $0.06 from our ongoing restructuring programs and acquisition expenses. According to Reuters Estimates, analysts on an average are expecting the Company to report EPS of $0.56 for third quarter of 2011.
http://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=ENS×tamp=20101109215300
ENS HOD 29.42$ not bad.
EnerSys Issues Q3 2011 EPS Guidance
Tuesday, 9 Nov 2010 04:53pm EST
EnerSys announced that for third quarter of 2011, it expects adjusted net earnings per diluted share (EPS) to be between $0.59 and $0.63, which excludes an expected charge of $0.06 from our ongoing restructuring programs and acquisition expenses. According to Reuters Estimates, analysts on an average are expecting the Company to report EPS of $0.56 for third quarter of 2011.
http://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=ENS×tamp=20101109215300
DEAR 1.69$. we are slightly under the 200 day MA 1.79 and right aboove the 50 day 1.62$.
the price sticks in between thoose two lines. it will breakout from here its just a matter of time and direction the break will go.
EARNINGS ALERT: ENERSYS IS EXPECTED TO BEAT THE STREET CONSENSUS WHEN IT REPORTS EARNINGS (ENS)
Nov 08, 2010 (SmarTrend(R) News Watch via COMTEX) -- Analysts, on average, expect EnerSys (NYSE:ENS) to report earnings of $0.51 per share on sales of $444 million on November 10, 2010.
For the full year, analysts expect the company to post EPS of $2.14. In the year-ago period, the company reported EPS of $0.30 on sales of $367 million.
In the previous quarter, the company reported EPS of $0.48, missing consensus estimates of $0.49.
Write to Chip Brian at cbrian@tradethetrend.com
http://www.zacks.com/research/get_news.php?id=312l8877
UPDATE 1-American Science and Engineering Q2 beats, shares rise
AMERICAN SCIENCE AND ENGINEERING, INC.
ASEI.O
$84.65
+2.71+3.31%
8:07pm GMT+0100
OSI SYSTEMS, INC.
OSIS.O
$36.35
-1.04-2.79%
8:06pm GMT+0100
Tue Nov 9, 2010 1:18pm EST
* Q2 EPS $1.59 vs est $1.20
* Sales up 32 pct
* Shares touch three-year high
Nov 9 (Reuters) - Security systems maker American Science and Engineering (ASEI.O) posted better-than-expected quarterly results as rising significance of security in public places drove demand for its products, sending the shares up 4 percent to almost a three-year high.
The company, which makes x-ray inspection systems to protect high-threat facilities and help combat terrorism, trade fraud, and drug and weapon smuggling, said second-quarter bookings rose 29 percent to $116.2 million from a year ago.
American Science and Engineering is known for its high-margin Z Backscatter technology that can detect explosive materials hidden under a person's clothing. For the July-September quarter, the company earned $14.7 million, or $1.59 a share, compared with $10.7 million, or $1.18 a share, a year ago.
Sales at the company, which competes with OSI Systems Inc (OSIS.O), rose 32 percent to $80.6 million.
Analysts on average were expecting earnings of $1.20 a share on revenue of $71.2 million, according to Thomson Reuters I/B/E/S.
Shares of the Billerica, Massachusetts-based company were trading up 3 percent at $84.69 Tuesday afternoon on Nasdaq.
The company's shares, valued at $744.5 million, have risen 14 percent in value in the last six months. (Reporting by Soham Chatterjee in Bangalore; Editing by Vyas Mohan)
http://www.reuters.com/article/idUSSGE6A80PL20101109
DEAR 1.73$ setting up for a moove, either up or down...
All that Jazz :)
PWER 9.41$ shorts still downward presuring. how long can they keep on doing this?
2.76$ bear raid?
Jazz Pharmaceuticals Announces Adjusted Net Income for the Third Quarter of $0.41 per Share and GAAP Net Income of $0.32 per Share
PALO ALTO, Calif., Nov. 4, 2010 /PRNewswire via COMTEX/ -- Jazz Pharmaceuticals, Inc. /quotes/comstock/15*!jazz/quotes/nls/jazz (JAZZ 13.95, +1.55, +12.50%) today announced financial results for the third quarter ended September 30, 2010, and updated financial guidance for 2010. The company's updated 2010 financial guidance reflects higher expected sales of XYREM(R) (sodium oxybate) oral solution and lower expected expenses.
Total revenues for the quarter ended September 30, 2010 were $44.8 million, up 45 percent compared to $30.8 million for the quarter ended September 30, 2009. Total net product sales of Xyrem and LUVOX CR(R) (fluvoxamine maleate) extended-release capsules were $43.8 million, an increase of 46 percent from the third quarter of 2009.
For the third quarter of 2010, Xyrem net sales were $37.2 million, compared to $25.0 million for the third quarter of 2009, representing a 49 percent increase. The increase in Xyrem net sales in the third quarter of 2010 was primarily due to the impact of price increases, as well as to a lesser extent, an increase in prescription volume. Net sales of once-daily Luvox CR were $6.6 million for the quarter, up 33 percent compared to $5.0 million for the third quarter of 2009.
"These positive financial results and our increased guidance for 2010 highlight the success of our ongoing commercial operations, particularly the strength of our Xyrem business," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "We look forward to gaining clarity from the FDA regarding next steps for JZP-6 in fibromyalgia, and as we look towards 2011, we remain committed to delivering attractive earnings growth driven by strong sales of our currently marketed products."
Research and development expenses were $7.3 million for the quarter ended September 30, 2010, compared to $7.6 million for the quarter ended September 30, 2009. Selling, general and administrative expenses for the quarter ended September 30, 2010 were $18.0 million, compared to $15.1 million for the quarter ended September 30, 2009. The increase in selling, general and administrative expenses was due to higher personnel costs, including stock-based compensation, and activities related to the company's JZP-6 product candidate.
Interest expense for the third quarter of 2010 was $1.2 million, compared to $5.4 million for the prior year period. The significant decline in interest expense reflects a substantially lower principal amount of outstanding debt at a lower interest rate than in 2009.
For the third quarter of 2010, the company reported GAAP net income of $13.2 million, or $0.32 per diluted share, compared to a GAAP net loss of $1.7 million, or $0.05 per diluted share, for the quarter ended September 30, 2009.
Adjusted net income for the third quarter of 2010 was $17.2 million, or $0.41 per diluted share, compared to $2.1 million, or $0.06 per diluted share, for the same period of 2009. Adjusted net income (loss) and adjusted net income (loss) per diluted share are non-GAAP financial measures that exclude from GAAP net income (loss) and GAAP net income (loss) per diluted share revenue related to upfront and milestone payments, and certain expenses comprised of loss on extinguishment of debt, amortization of intangible assets, stock-based compensation and non-cash interest expense associated with debt discount and debt issuance costs. A reconciliation of adjusted net income (loss) and adjusted net income (loss) per diluted share to GAAP net income (loss) and GAAP net income (loss) per diluted share is available in a table included at the end of this press release.
Updated 2010 Guidance
Jazz Pharmaceuticals is revising its full year 2010 guidance to increase the company's adjusted net income per share guidance and provide updated estimates of full year product sales and operating expenses. The new financial guidance for 2010 is as follows:
Total product sales, net $164 - $168 million
Xyrem $140 - $142 million
Luvox CR $24 - $26 million
Gross margin greater than 90%
SG&A expenses $69 - $71 million
R&D expenses $27 - $28 million
GAAP net income per diluted
share $0.70 - $0.75
Adjusted net income per diluted
share(1) $1.45 - $1.50
(1) A reconciliation to GAAP net income per diluted share is
available in a table at the end of this press release.
Investor Conference Call
Jazz Pharmaceuticals will host an investor conference call and live audio webcast today (November 4, 2010) at 4:30 PM Eastern Time/1:30 PM Pacific Time to discuss its third quarter financial results and guidance for 2010, and provide a company update. The live webcast may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. Investors may participate in the conference call by dialing 866-770-7125 in the U.S., or 617-213-8066 outside the U.S., and entering passcode 61488979.
An archived version of the webcast will be available for at least one week on the Investors section of the Jazz Pharmaceuticals' website at www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see www.jazzpharmaceuticals.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' future financial performance, financial position and earnings growth potential, including 2010 financial guidance, future sales of its currently-marketed products and expenses. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: Jazz Pharmaceuticals' ability to increase sales of its Xyrem and Luvox CR products; Jazz Pharmaceuticals' dependence on single source suppliers and manufacturers as well as Jazz Pharmaceuticals' ability to obtain adequate clinical and commercial supplies of its product candidates, products and materials from current and potential new suppliers; Jazz Pharmaceuticals' dependence one central pharmacy distributor for Xyrem sales in the United States; Jazz Pharmaceuticals' cash flow estimates and the sufficiency of its cash resources; competition, including from potential generic competitors; Jazz Pharmaceuticals' ability to obtain and maintain intellectual property protection for its products and product candidates; and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on August 11, 2010. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.
shorts are already covering their position PWER 9.95$
http://www.marketintellisearch.com/articles/1073028.html
you did hit the low with your question at 9.53$.
Whole Foods Market Reports Fourth Quarter Results
Nov. 3, 2010, 4:02 p.m. EDT
Identical Store Sales Increase 8.7% and Accelerate to 6.4% on a Two-Year Basis; Company Produces 4.8% Operating Margin, $0.33 in Earnings Per Share and Raises Outlook for Fiscal Year 2011 by $0.07 Per Share
AUSTIN, Texas, Nov 3, 2010 (GlobeNewswire via COMTEX) -- Whole Foods Market, Inc. /quotes/comstock/15*!wfmi/quotes/nls/wfmi (WFMI 44.41, +3.34, +8.13%) today reported results for the 12-week fourth quarter and 52-week fiscal year ended September 26, 2010.
Sales for the quarter increased 15% to $2.1 billion. Comparable and identical store sales increased 8.7%, or 7.7% and 6.4% on a two-year stacked basis, respectively. Year over year, earnings before interest, taxes, depreciation and amortization ("EBITDA") increased 26% to $165.4 million, income available to common shareholders increased 101% to $57.5 million, and diluted earnings per share increased 63% to $0.33.
"Our ability to perform against tougher sales comparisons has continued to surpass our expectations, translating to better-than-expected identical store sales growth of 8.7% in the fourth quarter, an acceleration to 6.4% on a two-year basis. We are proud to be gaining market share at a faster rate than most public food retailers," said John Mackey, co-chief executive officer and co-founder of Whole Foods Market. "We attribute much of our success to the progress we have made in our relative price positioning and to our initiatives in areas such as healthy eating, animal welfare and sustainable seafood. These initiatives are aligned with our core customer base and reinforce our position as the authentic retailer of natural and organic foods, further differentiating the Whole Foods Market shopping experience and making us the preferred choice for customers aspiring to a healthier lifestyle."
The Company's comparable and identical store sales results for the last five quarters and first five weeks of the first quarter through October 31, 2010 are shown in the following table.
http://www.marketwatch.com/story/whole-foods-market-reports-fourth-quarter-results-2010-11-03?reflink=MW_news_stmp
QCOM 50$ US STOCKS-Markets rise on Fed; Qualcomm, Whole Foods up late
Fed announcement spurs volatile session
* VIX rises, then falls after Fed news
* Indexes up: Dow 0.2 pct, S&P 0.4 pct, Nasdaq 0.3 pct
* For up-to-the-minute market news see [STXNEWS/US] (Updates to add Qualcomm and Whole Foods results in paragraphs 6-7)
By Ryan Vlastelica
NEW YORK, Nov 3 (Reuters) - U.S. stocks ended a volatile session modestly higher on Wednesday after the Federal Reserve detailed a plan to breathe new life into the struggling economy.
Both the Dow and Nasdaq closed at levels not seen since 2008 while the S&P ended at a six-month high. The gains were preceded by an erratic session in which equities zigzagged up and down as the Fed announced a plan to buy $600 billion in Treasuries. The size of the plan was greater than had been anticipated but less than many hoped. For details, see [ID:nN03120542]
"The question is whether this is enough. The consensus was $500 billion over the next six months or so. This is just a little bit ahead," said Jeff Kleintop, chief market strategist at LPL Financial, Boston.
The S&P has risen about 14 percent since the start of September as investors bet on the Fed's action and Republican gains in Tuesday's elections, two suppositions that came to pass and ended some of the market's uncertainty.
The CBOE Volatility index .VIX, a favored gauge of investor anxiety, fell 9 percent after rising earlier. The change in direction "indicates... that traders feel the Fed support under the market remains firm and that we are likely to see higher highs in the stock benchmarks," said Jon Najarian, a co-founder of web information site Optionmonster.com in Chicago.
Qualcomm Inc (QCOM.O) rose 8.3 percent to $49.49 in extended-trading after it reported fourth-quarter revenue that beat expectations. [ID:nN03126519].
Whole Foods Market Inc (WFMI.O) rose 8 percent to $44.34 after the market's close on a higher-than-expected profit. [ID:nN03118403].
The Dow Jones industrial average .DJI was up 26.41 points, or 0.24 percent, at 11,215.13. The Standard & Poor's 500 Index .SPX was up 4.39 points, or 0.37 percent, at 1,197.96. The Nasdaq Composite Index .IXIC was up 6.75 points, or 0.27 percent, at 2,540.27.
The Nasdaq ended at its highest since June 2008 while the Dow closed at its highest since September 2008. The S&P 500 closed at its best level in six months.
The S&P 500 broke through its 200-week moving average, which was seen signaling further gains.
The Republicans' strong gains in the election, including regaining control of the House and increasing their numbers in the Senate, would be more business friendly, investors said. <^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ For stories on the U.S. elections: [ID:nUSVOTE] For a graphic on the election results:
PWER 9.90$ Option Action in Power-One Suggests Big Price Move Forthcoming (PWER)
Written on Tue, 11/02/2010 - 8:42am
By Chip Brian
Shares of Power-One (NASDAQ:PWER) traded 8.5% lower yesterday, closing at $9.53. The stock has been drifting lower over the past nine trading days but is currently trading in a technical uptrend.
The call volume yesterday was 16,695 contracts, which is 3x the average daily volume of 4,783. The put volume was 7,835 contracts, which is 4x the average daily volume of 1,978. Heavy volume in both puts and calls suggests that traders are expecting a big move but are unsure of direction.
SmarTrend is currently bullish and has Power-One in a technical uptrend. We are now watching for any positive developments that could result in a new uptrend signal.
http://www.mysmartrend.com/news-briefs/news-watch/option-action-power-one-suggests-big-price-move-forthcoming-pwer
Earnings Alert: Jazz Pharmaceuticals is Expected to Beat the Street Consensus When It Reports Earnings (JAZZ)
Written on Mon, 11/01/2010 - 10:30am
By Chip Brian
Analysts, on average, expect Jazz Pharmaceuticals (NASDAQ:JAZZ) to report earnings of $0.33 per share on sales of $43 million on November 04, 2010 After Market Close.
For the full year, analysts expect the company to post EPS of $1.10. In the year-ago period, the company reported EPS of $0.02 on sales of $31 million.
In the previous quarter, the company reported EPS of $0.22, topping consensus estimates of $0.09.
http://www.mysmartrend.com/news-briefs/news-watch/earnings-alert-jazz-pharmaceuticals-expected-beat-street-consensus-when-it-re
well its sitting right at the under boli. 9$ was a good support in the past. i just could tel you from chartspeakingwise but i guess you know the charts. the shortinteresst is huge here. loool
gotta wait for them to cover.
PWER 9.65$
MNI is at 2.60$ again!
congrats to all. i almost stoped believing this week and they nearly have shaked me out. huge props to the strong DD here, again!
god bless
loool i am not serious at all with that. i like the ironic of it, who would do that?? who???? lol
dont forget to come back when the shorts are done .
loool from 13$ down to 10.50$ this stock is really dangerous. but what else can we expect with such a high short interesst.
hmm im thinking of buying the calls again. they closed the gap in nearly 15min? lol and price target could be 13$ by end of the year. what u think?
dont let them scare you they get you shourt just to ride it back up. watch.
back down where you came from loool
yeah looks good. Pre_market is up at 13.15$ the options should open with a bang. lol
WEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE :D
Bloomberg News: Avanir Short-Sale Bets Rise to Record Before Oct. 30 U.S. Ruling on Drug
Investors are making a record number of bets against Avanir Pharmaceuticals Inc. shares and pushing options prices to a four-year high before U.S. regulators rule on the drugmaker’s proposed neurological therapy by Oct. 30.
Avanir, based in Aliso Viejo, California, is seeking approval of the drug, AVP-923, to reduce bouts of involuntary laughing and crying among patients who have suffered brain injuries or have multiple sclerosis or Lou Gehrig’s disease, also known as amyotrophic lateral sclerosis.
Four analysts surveyed by Bloomberg have a buy rating on the shares and two issued notes this month predicting approval. A report, “Nine Reasons to Sell Avanir,” sent to investors Monday by Favus Institutional Research LLC, predicted the drug wouldn’t be approved by the Food and Drug Administration due to concerns over heart safety, said Elliot Favus, the firm’s co- founder.
“Our view is that there’s no dose of the drug that doesn’t cause a delay in electrical conduction of the heart and we think that’s a concern for the FDA,” Favus said in a telephone interview yesterday.
Avanir rose 8 cents, or 3 percent, to $2.79 at 12:55 p.m. in Nasdaq Stock Market composite trading and has gained 41 percent in the twelve months before today.
AVP-923 is a combination of quinidine, a generic drug that prevents heart arrhythmia, and dextromethorphan, a cough suppressant. The combination is thought to affect the neurotransmitter glutamate, Avanir has said.
Short Selling
More than 26 percent of the company stock available for trading, or float, were sold short as of Oct. 26, up from 11 percent two months ago and a 2010 low of 6.3 percent in January, according to data compiled by Bloomberg and Data Explorers, a New York-based research firm that tracks short sales. Implied volatility, the key gauge of option prices, for at-the-money Avanir contracts expiring in 30 days has doubled in the past six weeks to 357.49.
Short sellers profit from the decline in share prices by selling borrowed securities and later replacing them with shares bought at lower levels. Investors use options to guard against fluctuations in the price of securities they own, speculate on share-price moves or bet that volatility, or stock swings, will rise or fall.
Avanir presented results of a study at the American Academy of Neurology’s annual meeting in Toronto on April 13 showing that patients reported fewer episodes of involuntary laughing and crying after taking the medication. The uncontrolled displays of emotion are known as pseudobulbar affect.
2006 FDA Rejection
The FDA rejected the drug in 2006, citing concerns over heart rhythm safety, said Ritu Baral, an analyst for Cannacord Genuity in New York. The agency’s chief concern was whether quinidine caused QT prolongation, a change in electrical rhythm that can increase the risk of heart attacks, she said.
The company then reformulated the drug with a lower dose of quinidine and conducted new studies, she said.
“We view all the safety data, including heart rhythm safety data, as clean,” Baral said in a telephone interview yesterday. “We don’t think FDA will delay approval.”
There is a 75 percent chance the FDA will clear the drug and that Avanir will begin marketing it in the first half of 2011, Baral said in a note yesterday to investors.
The options market is assigning an equal probability that the stock will plunge below $1 or soar above $7.50 because prices for November options to bet on moves to those levels are the same, said Ophir Gottlieb, head of client services at Livevol Inc., a San Francisco-based provider of options market analytics.
“The options market is implying it’s equally likely that the company triples in value or goes bankrupt,” Gottlieb said. “If the experts are guessing there will be a good result, the options market isn’t buying it.”
To contact the reporters on this story: Rob Waters in San Francisco at rwaters5@bloomberg.net; Jeff Kearns in New York at jkearns3@bloomberg.net.
To contact the editors responsible for this story: Nick Baker at nbaker7@bloomberg.net; Reg Gale at rgale5@bloomberg.net.
http://www.bloomberg.com/news/2010-10-28/avanir-short-sale-bets-rise-to-record-before-oct-30-fda-ruling-on-drug.html
shows 2.15$ AH lets see what happens.
no i wont cha let play games with my money if i dont get a piece of the cake! so for today i said my point. suprise me with a good tomorrow!
peace.
LAZ is one of the BEST stocks today and further!
Virgin Media – Third Quarter 2010 Results
Virgin Media Inc. (MM) (NASDAQ:VMED)
Intraday Stock Chart
Heute : Wednesday 27 October 2010
Virgin Media Inc. (NASDAQ: VMED; LSE: VMED) announces results for the quarter ended September 30, 20101.
Revenue growth in all segments drives strong financial performance
Total revenue up 6.4% to £978m
Revenue growth in all areas, including strong growth in both Mobile and Business
Fourth successive quarter of double-digit percentage OCF2 growth, up 11.0% to £387m
Operating income doubled to £102m from £51m
Free cash flow3 up 8.6% to £119m; last 12 months FCF up 18.2% versus previous 12 months
Operational performance driven by continued ARPU and customer increases
Cable ARPU up 3.7% to a record £46.38
Cable customers up 1.9% with 14,100 net new cable customers in Q3, up from 8,100 a year ago
Cable gross additions of 236,000 up 10.4%
Triple-play penetration increased to 62.7% and quad-play penetration increased to 11.5%, reflecting focus on bundling
Pre-registration for UK’s fastest widely available broadband opens today; 100Mb broadband service further extends Virgin Media’s speed advantage
Continued improvement of Company’s capital structure
Accelerated Stock Buyback programme of £125m completed; Board authority remains for £250m of further buybacks
Effective increase of Convertible strike price from $19.22 to $35
Execution of conversion hedges against 90% of convertible notes
Would reduce future dilution by 21m shares, assuming $35 stock price in 2016
Existing convertible noteholders unaffected
Neil Berkett, Chief Executive Officer of Virgin Media, said: “Our continued focus on exploiting our strategic advantages with the resulting multiple opportunities for revenue growth, as well as robust financial discipline has delivered another strong financial performance this quarter. We are extending our lead in broadband even further with the imminent availability of 100Mb as consumer demand for consistently faster broadband grows.
“Our confidence in our long term ability to maximize our advantages to deliver strong free cash flow means we have been able to begin to execute on our plans to return capital to stockholders. We have completed an initial buyback of £125m of stock and retain the authority for a further £250m in the coming months. Today, we have also announced, the execution of conversion hedges which should further benefit stockholders by effectively increasing the strike price of our convertible notes to $35.”
1 Comparisons of financial and operating statistics are to the third quarter of 2009, unless otherwise stated.
2 OCF is operating income before depreciation, amortization, goodwill and intangible asset impairments and restructuring and other charges and the most directly comparable GAAP measure is operating income. OCF is a non-GAAP financial measure. Please see Appendix F for a reconciliation of non-GAAP financial measures to their nearest GAAP equivalents.
3 Free Cash Flow is OCF reduced by purchase of fixed and intangible assets, as reported in our statements of cash flows, and net interest expense, as reported in our statements of operations, and the most directly comparable GAAP measure is net cash provided by operating activities. FCF is a non-GAAP financial measure. Please see Appendix F for a reconciliation of non-GAAP financial measures to their nearest GAAP equivalents.